Table 2

Comparison of HAM-D scores for patients with a major depressive episode over 6-week treatment with WS® 5570 or placebo (full analysis set; last observation carried forward)

HAM-D measure
WS® 5570 600 mg/day N = 119
WS® 5570 1200 mg/day N = 124
Placebo N = 81
p-value











WS® 5570 600 mg/day vs placebo
WS® 5570 1200 mg/day vs placebo

Total score (mean ± SD)
Day 0
22.8 ± 3.3
22.6 ± 3.8
23.6 ± 4.2
0.14
0.09

Day 14
17.9 ± 6.3
18.2 ± 6.6
19.1 ± 20
0.23
0.34

Day 42
11.2 ± 7.0
11.8 ± 8.3
17.6 ± 8.8
<0.001
<0.001
Difference vs day 0 (mean ± SD)
Day 14
-4.9 ± 5.1
-4.5 ± 4.7
-4.5 ± 5.4
0.65
0.95

Day 42
-11.6 ± 6.4
-10.8 ± 7.3
-6.0 ± 8.1
<0.001
<0.001
Mean reduction vs day 0 (%)
Day 14
22.0%
20.9%
16.7%
0.54
0.77

Day 42
57.9%
57.1%
16.7%
<0.001
<0.001

Comparison vs placebo for difference day 42 vs day 0
WS® 5570 600 mg/day vs placebo
WS® 5570 1200 mg/day vs placebo


Differences in means*
-5.6
-4.8


95% confidence interval
[-7.7, -3.6]
[-6.9, -2.6]


p-value
<0.001
<0.001



*A negative difference denotes a more favorable outcome in the treatment group named first.

Kasper et al. BMC Medicine 2006 4:14   doi:10.1186/1741-7015-4-14